title: Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
abstract: In a group of 126 Australian patients with haemophilia, who were receiving lyophilized clotting-factor concentrates prepared from locally collected plasma, a high prevalence of antibody to human T-cell lymphotropic virus III (HTLV-III) was demonstrated in those with severe disease. Patients with moderate or mild disease had a much lower prevalence of HTLV-III antibody. After heat treatment of lyophilized factor VIII and factor IX concentrates (60 degrees C for 72 hours) to inactivate the virus, the losses of activity of an intermediate-purity and of a fibrinogen-poor factor VIII concentrate, and of the coagulant activity of a factor IX concentrate, were within acceptable limits. The solubility of the intermediate-purity factor VIII concentrate was markedly decreased; the fibrinogen-poor factor VIII concentrate and the factor IX concentrate were readily soluble. In-vivo recovery and survival of heated concentrates were equivalent to those of the unheated products, and they were effective in the treatment of spontaneous and traumatic haemorrhages.
authors.forename: K M
authors.initials: KM
authors.lastname: McGrath
authors.forename: K B
authors.initials: KB
authors.lastname: Thomas
authors.forename: R W
authors.initials: RW
authors.lastname: Herrington
authors.forename: P J
authors.initials: PJ
authors.lastname: Turner
authors.forename: L
authors.initials: L
authors.lastname: Taylor
authors.forename: H
authors.initials: H
authors.lastname: Ekert
authors.forename: P
authors.initials: P
authors.lastname: Schiff
authors.forename: I D
authors.initials: ID
authors.lastname: Gust
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000635:transmission; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D017977:Deltaretrovirus / Q000276:immunology*; D005164:Factor IX / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D005169:Factor VIII / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D006358:Hot Temperature; D006801:Humans
chemical_list: D000914:Antibodies, Viral; D005169:Factor VIII; D005164:Factor IX